Description
A substituted diarylimidazole inhibitor of P-glycoprotein ATPase activity (IC50 = 0.16 µM); reverses drug resistance to doxorubicin, vinblastine, and paclitaxel in human lymphoma, breast, ovarian, uterine, and colorectal cancer cell lines (EC50s = 9-38 nM); not cytotoxic at concentrations up to 100 µM; exhibits weak cytostatic activity (average IC50 = >60 µM); reduces paclitaxel drug resistance in an HCT15 human colon carcinoma mouse xenograft model at 30 mg/kg
Formal name: 4-[2-[4-[(1E)-3-ethoxy-1-propen-1-yl]phenyl]-4-[4-[(1-methylethyl)amino]phenyl]-1H-imidazol-5-yl]-N-(1-methylethyl)-benzenamine
Synonyms: OC 144093
Molecular weight: 494.7
CAS: 216227-54-2
Purity: ≥98%
Formulation: A crystalline solid
